On Monday, the FTC told Illumina to dissolve their acquisition with the multi-cancer early detection test company Grail. David Lim talks with host Ben Leonard about what this move means for the development and commercialization of cancer tests in the United States.
On Monday, the FTC told Illumina to dissolve their acquisition with the multi-cancer early detection test company Grail. David Lim talks with host Ben Leonard about what this move means for the development and commercialization of cancer tests in the United States.